Abstract | BACKGROUND: The brief period of viral replication in recurrent herpes labialis lesions suggests shorter therapeutic regimens are a logical episodic treatment strategy. OBJECTIVE: We sought to assess the efficacy and safety of single-dose and single-day famciclovir treatments. METHODS: RESULTS: Median healing times of primary (first to appear) vesicular lesions in the famciclovir single-dose, famciclovir single-day, and placebo groups were 4.4, 4.0, and 6.2 days, respectively. There was no significant difference between the famciclovir regimens. Adverse events in the famciclovir groups were similar to placebo. LIMITATIONS: The active arms of this trial were not directly compared to other antiviral regimens. CONCLUSION:
|
Authors | Spotswood L Spruance, Neil Bodsworth, Harvey Resnick, Marcus Conant, Claude Oeuvray, Joseph Gao, Kamal Hamed |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 55
Issue 1
Pg. 47-53
(Jul 2006)
ISSN: 1097-6787 [Electronic] United States |
PMID | 16781291
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiviral Agents
- 2-Aminopurine
- Famciclovir
|
Topics |
- 2-Aminopurine
(administration & dosage, analogs & derivatives)
- Administration, Oral
- Adult
- Antiviral Agents
(administration & dosage)
- Double-Blind Method
- Famciclovir
- Female
- Herpes Labialis
(drug therapy)
- Humans
- Male
- Self Administration
- Time Factors
|